Biocon Ltd.

Biocon Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent downgrade in daily price performance, the company’s longer-term technical outlook remains cautiously optimistic, supported by a recent upgrade in its Mojo Grade from Hold to Buy.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy as of 11 March 2026. This upgrade reflects a comprehensive reassessment of the company’s quality, valuation, financial trends, and technical outlook, underpinned by robust quarterly results and favourable market performance.

Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 4 March 2026. This adjustment reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technical indicators. Despite strong long-term returns and improving fundamentals, recent technical signals and valuation metrics have prompted a more cautious stance among analysts.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a blend of bullish and bearish signals across key indicators. With a recent upgrade in its Mojo Grade from Hold to Buy and a current Mojo Score of 74.0, the stock’s technical landscape warrants a detailed examination to understand its near-term trajectory and investment appeal.

Biocon Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy, reflecting a marked improvement across technical indicators, valuation metrics, financial trends, and overall quality. This upgrade, effective from 26 February 2026, is underpinned by a comprehensive analysis of the company’s recent performance and market positioning.

Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is underscored by a complex interplay of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest an improving price momentum despite some mixed signals on longer-term charts.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market participation and potential directional bets. This development comes alongside a steady price appreciation and rising investor interest, positioning the stock for closer scrutiny by market participants.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market activity and shifting investor positioning. The stock’s recent performance, combined with rising volumes and improved delivery statistics, suggests a growing bullish sentiment despite a slight underperformance relative to its sector peers.

Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.6% increase in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a steady price appreciation and rising delivery volumes, suggesting evolving market sentiment and potential directional bets on the stock.

Biocon Ltd. is rated 'Hold' by MarketsMOJO, a rating that was last updated on 13 October 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Biocon Ltd. is rated 'Hold' by MarketsMOJO, a rating that was last updated on 13 October 2025. While this rating change occurred several months ago, the analysis below reflects the stock’s current position as of 23 February 2026, incorporating the latest financial metrics, returns, and market data.

Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant shift in its valuation parameters, moving from an 'attractive' to a 'very attractive' rating. This change reflects evolving market perceptions and valuation metrics, notably in price-to-earnings (P/E) and price-to-book value (P/BV) ratios, which now position the stock favourably against its historical averages and peer group. Despite mixed returns relative to the broader Sensex, Biocon's valuation realignment offers investors a fresh perspective on its price attractiveness amid sector headwinds.

Biocon Limited, India's largest integrated biopharmaceutical company with a market capitalisation of ₹60,687 crores, delivered a remarkable turnaround in Q3 FY26, reporting consolidated net profit of ₹143.80 crores—a stunning 472.91% year-on-year surge from ₹25.10 crores in Q3 FY25. However, the quarter presented a mixed narrative as net sales declined 2.85% sequentially to ₹4,173.00 crores, even whilst posting a healthy 9.20% year-on-year growth. Following the results announcement, the stock has gained 2.64% over the past week, trading at ₹377.40 as of February 12, 2026, though it remains 11.19% below its 52-week high of ₹424.95.

Biocon Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 11.4% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in the stock price, the increase in OI alongside rising volumes suggests evolving directional bets and a complex interplay of bullish and bearish sentiments among traders.

Biocon Ltd. is rated 'Hold' by MarketsMOJO, a rating that was last updated on 13 October 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 February 2026, providing investors with the latest insights into its performance and outlook.